Evidence map›Paper›PMID 32712168›Full record

ArticleKidney international2021

A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis.

Cihan Heybeli, Andrew Bentall, Jiqiu Wen, Mariam Priya Alexander, Francis K Buadi, Fernando G Cosio, Patrick G Dean, Angela Dispenzieri, David Dingli, Mireille El Ters and 15 more

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. The Dawn of a New Era in Kidney Transplantation: Promises and Limitations of Artificial Intelligence for Precision Diagnostics.Transplant international : official journal of the European Society for Organ Transplantation · 2023
    Article
  7. Outcomes of kidney transplantation in patients with myeloma and amyloidosis in the USA.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2022
    Article
  8. Observational
  9. Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)-Associated Lesions: A Case Series.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2022
    Article
  10. Amyloidosis of the Heart and Kidney.Methodist DeBakey cardiovascular journal · 2022
    Review
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 4 institutions in 3 countries.

Cihan HeybeliDivision of Nephrology, Dokuz Eylul University School of Medicine, Izmir, Turkey; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Andrew BentallDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Jiqiu WenNational Clinical Research Center of Kidney Disease, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.
Mariam Priya AlexanderDepartment of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Francis K BuadiDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Fernando G CosioDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Patrick G DeanDivision of Transplantation Surgery, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Angela DispenzieriDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
David DingliDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Mireille El TersDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Morie A GertzDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Amer HatemDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Prashant KapoorDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Hasan KhamashDivision of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona, USA.
Taxiarchis KourelisDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Shaji KumarDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Elizabeth C LorenzDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Martin MaiTransplant Center, Mayo Clinic, Jacksonville, Florida, USA.
Eli MuchtarDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
David L MurrayDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Mikel PrietoDivision of Transplantation Surgery, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Carrie A SchinstockDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Mark D StegallDivision of Transplantation Surgery, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Rahma WarsameDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Nelson LeungDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: Leung.Nelson@mayo.edu.
Mayo Clinic · USMayo Clinic in Florida · USWinnMed · USNanjing University · CN

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Peter Leif Bergsagel · 2015 to 2026
$25.5M
Improving frailty and long-term outcomes after kidney transplantationK23DK123313 · NIDDK · MAYO CLINIC ROCHESTER · PI LORENZ, ELIZABETH C. · 2019 to 2023
$795k
NCI NIH HHS P50 CA186781NIDDK NIH HHS K23 DK123313
6 · The paper itself

Abstract

Longer survival using modern therapies has increased the number of patients with immunoglobulin light-chain amyloidosis receiving kidney transplantation. We evaluated 60 patients with immunoglobulin light chain amyloidosis who underwent kidney transplantation based on their hematologic response for outcomes of death, graft failure, and complications. Patient hematologic responses (light-chain in blood or urine) prior to kidney transplantation were three patients had no response, five had a partial response, six had a very good partial response, 37 had a complete response, and nine were treatment-naive patients (never treated for this disorder). After transplantation, seven of nine treatment-naive patients achieved a complete response. The median follow-up for the entire transplant cohort was 61 months. The estimated median overall survival from the time of kidney transplantation was 123 months for the entire group. Median overall survival was not reached for the very good partial response plus complete response groups, it was 47 months for no response plus partial response groups, and 117 months for the treatment-naive group (all significantly different). Median overall survival of very good partial response was 81 months, while the median was not reached in the complete response group (no significant difference). The time to amyloid recurrence was significantly longer in complete response compared to very good partial response (median 181 vs 81 months). Death-censored graft survival at one- and five-years was 98.3%, and 95.8%, respectively for all groups. Of the 60 patients, three had allograft failure, 19 died with a functioning graft, and 13 had an amyloid recurrence. Thus, outcomes after kidney transplant in patients with immunoglobulin light-chain amyloidosis seem acceptable if a very good partial response or complete response is achieved either before or after transplantation.

Indexed as

AmyloidosisImmunoglobulin Light-chain AmyloidosisKidney TransplantationHumansImmunoglobulin Light ChainsNeoplasm Recurrence, LocalTreatment OutcomeImmunoglobulin Light Chainskidney transplantationmass spectrometrymonoclonal gammopathy

Identifiers

PMID32712168
PMCPMC8411566
OpenAlexW3044855616

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.